- Home
- HHS vs TARA Comparison
HHS vs TARA Comparison
Compare HHS & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HHS
- TARA
- Stock Information
- Founded
- HHS 1923
- TARA N/A
- Country
- HHS United States
- TARA United States
- Employees
- HHS N/A
- TARA N/A
- Industry
- HHS Advertising
- TARA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HHS Consumer Discretionary
- TARA Health Care
- Exchange
- HHS Nasdaq
- TARA Nasdaq
- Market Cap
- HHS 52.3M
- TARA 52.4M
- IPO Year
- HHS N/A
- TARA N/A
- Fundamental
- Price
- HHS $6.97
- TARA $2.61
- Analyst Decision
- HHS
- TARA Strong Buy
- Analyst Count
- HHS 0
- TARA 2
- Target Price
- HHS N/A
- TARA $24.00
- AVG Volume (30 Days)
- HHS 13.5K
- TARA 227.1K
- Earning Date
- HHS 11-14-2024
- TARA 11-12-2024
- Dividend Yield
- HHS N/A
- TARA N/A
- EPS Growth
- HHS N/A
- TARA N/A
- EPS
- HHS N/A
- TARA N/A
- Revenue
- HHS $187,093,000.00
- TARA N/A
- Revenue This Year
- HHS N/A
- TARA N/A
- Revenue Next Year
- HHS $4.05
- TARA N/A
- P/E Ratio
- HHS N/A
- TARA N/A
- Revenue Growth
- HHS N/A
- TARA N/A
- 52 Week Low
- HHS $6.45
- TARA $1.04
- 52 Week High
- HHS $8.87
- TARA $5.24
- Technical
- Relative Strength Index (RSI)
- HHS 34.77
- TARA 71.79
- Support Level
- HHS $6.90
- TARA $2.43
- Resistance Level
- HHS $7.26
- TARA $2.74
- Average True Range (ATR)
- HHS 0.23
- TARA 0.20
- MACD
- HHS -0.03
- TARA 0.02
- Stochastic Oscillator
- HHS 4.23
- TARA 90.12
About HHS Harte-Hanks Inc.
Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).